FDA Refreshes Guide to Keep Your Salad from Plotting Revenge
Published Date: 8/12/2026
Rule
Summary
The Food and Drug Administration (FDA or we) is announcing the availability of a final guidance for industry entitled "Guide to Minimize Biological Hazards in Ready-to-Eat Fresh-Cut Produce." This guidance supersedes a previous guidance, entitled "Guide to Minimize Microbial Food Safety Hazards of Fresh-Cut Fruits and Vegetables," issued in 2008, and is a final guidance to the draft guidance for industry entitled "Guide to Minimize Food Safety Hazards of Fresh-Cut Produce" issued in 2018. The guidance is intended to help manufacturers or processors of ready-to-eat fresh-cut produce that is not a low-moisture food comply with applicable requirements in our regulations on current good manufacturing practices for hazard analysis and risk-based preventive controls for human food.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Final Guidance Helps Fresh‑Cut Processors
If you manufacture or process ready-to-eat fresh-cut produce that is not a low‑moisture food, the FDA published a final guidance on August 12, 2026 to help you comply with current good manufacturing practices and hazard analysis and risk-based preventive controls in 21 CFR part 117.
Scope Clarified by Water Activity Limit
The guidance explicitly applies only to ready-to-eat fresh-cut produce with a water activity above 0.85, so if your product's water activity is above 0.85 this guidance is intended to cover your operations.
New Examples For Process Controls Included
The final guidance adds another example of an antimicrobial substance that can be used as a process control, gives additional examples of supply‑chain programs to control pathogens, and offers more recommendations on time and temperature controls for fresh‑cut processing.
No New Paperwork Burden Noted
The guidance contains no new collections of information and refers to previously approved collections in 21 CFR part 117 under OMB control number 0910-0751, so it does not add new paperwork requirements.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16353, Reauthorization of the Generic Drug User Fee Amendments; Public Meeting; Request for Comments
The Food and Drug Administration (FDA, the Agency, or we) is hosting a public meeting to discuss proposed recommendations for the reauthorization of the Generic Drug User Fee Amendments (GDUFA) for fiscal years (FYs) 2028 to 2032. GDUFA amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) to authorize FDA to assess and collect fees to support human generic drug activities. The current legislative authority for GDUFA expires at the end of September 2027. At that time, new legislation will be required for FDA to continue to assess and collect generic drug user fees for future fiscal years. The FD&C Act directs FDA, following negotiations with the regulated industry and periodic consultations with other stakeholders, to present recommendations for reauthorization of the GDUFA program to the relevant Congressional committees, publish the recommendations in the Federal Register, provide for a period of 30 days for the public to provide written comments on such recommendations, and hold a meeting at which the public may present its views on such recommendations. FDA will then consider such public views and comments and revise such recommendations as necessary.
2026-16209, Radiology Devices; Reclassification of Digital Breast Tomosynthesis System
The FDA wants to change how digital breast tomosynthesis (DBT) systems are classified, moving them from a strict, high-level category (Class III) to a more flexible one (Class II) with special safety rules. This affects companies making these breast imaging devices, making it easier and faster to get them approved. Comments on this change are open until October 9, 2026, so stakeholders should act fast to share their thoughts!
2026-16248, Determination That OZOBAX (Baclofen) Oral Solution, 5 Milligrams/5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that OZOBAX (baclofen) oral solution, 5 milligrams (mg)/5 milliliters (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.
Previous / Next Documents
Previous: 2026-16413, Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
The Drug Enforcement Administration issues this temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1- hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing O-DSMT in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.
Next: 2026-16425, Rescission of DOE's Procedures for Traffic Control on the Nevada Test Site
This interim final rule rescinds DOE's regulations outlining the establishment of traffic control regulations on the Nevada National Security Site (NNSS), formerly known as the Nevada Test Site. This action is being taken to remove regulations that are obsolete because the NNSS uses Nevada traffic enforcement statutes. The effect of this action will be the removal of obsolete regulations.